靶向治疗COVID-19中的急性肾损伤
住院患者中急性肾损伤(AKI)发生率高达43%,且AKI与住院死亡率强相关。AKI的病理生理机制涉及免疫炎症反应、组织缺氧、肾灌注减少、内皮损伤及病毒直接感染上皮细胞,线粒体代谢重编程是关键。针对AKI的治疗策略可能改善COVID-19预后,且源于脓毒症、缺血再灌注等领域的干预措施可快速转化。
要点
- COVID-19住院患者AKI发生率高达43%,与其它肺炎和心脏手术相当。
- AKI与COVID-19住院死亡率强相关,无AKI患者死亡率很低。
- 靶向AKI的治疗可能改善COVID-19预后,已有脓毒症AKI策略可借鉴。
核心结论
- AKI在COVID-19住院患者中常见且与死亡率强相关,靶向AKI治疗具有合理性。
主要发现
- COVID-19住院患者AKI发生率高达43%,与其它需住院肺炎及心脏手术者相当。
- AKI与住院死亡率强相关,无AKI的COVID-19患者死亡率很低。
- AKI机制多因素:免疫炎症反应、组织缺氧、肾灌注减少、内皮损伤、病毒直接感染上皮细胞。
- 线粒体在代谢失调中起核心作用,应激条件下糖酵解增加、脂肪酸氧化减少。
临床怎么用
- 应重视COVID-19患者AKI的预防和管理,可能改善预后。
- 针对脓毒症、炎症和缺血再灌注等病因开发的AKI干预措施可快速转化用于COVID-19 AKI。
局限性
- AKI对COVID-19结局的影响目前难以评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As of 15 August 2020, Coronavirus disease 2019 (COVID-19) has been reported in >21 million people world-wide and is responsible for more than 750,000 deaths. The occurrence of acute kidney injury (AKI) in patients hospitalized with COVID-19 has been reported to be as high as 43%. This is comparable to AKI in other forms of pneumonia requiring hospitalization, as well as in non-infectious conditions like cardiac surgery. The impact of AKI on COVID-19 outcomes is difficult to assess at present but, similar to other forms of sepsis, AKI is strongly associated with hospital mortality. Indeed, mortality is reported to be very low in COVID-19 patients without AKI. Given that AKI contributes to fluid and acid-base imbalances, compromises immune response and may impair resolution of inflammation, it seems likely that AKI contributes to mortality in these patients. The pathophysiologic mechanisms of AKI in COVID-19 are thought to be multifactorial including systemic immune and inflammatory responses induced by viral infection, systemic tissue hypoxia, reduced renal perfusion, endothelial damage and direct epithelial infection with Severe Acute Respiratory Syndrome Coronavirus 2. Mitochondria play a central role in the metabolic deregulation in the adaptive response to the systemic inflammation and are also found to be vital in response to both direct viral damage and tissue reperfusion. These stress conditions are associated with increased glycolysis and reduced fatty acid oxidation. Thus, there is a strong rationale to target AKI for therapy in COVID-19. Furthermore, many approaches that have been developed for other etiologies of AKI such as sepsis, inflammation and ischemia-reperfusion, have relevance in the treatment of COVID-19 AKI and could be rapidly pivoted to this new disease.
引用
- Kellum JA, van Till JWO, Mulligan G, et al. Targeting acute kidney injury in COVID-19. Nephrol Dial Transplant. 2020. PMID: 33022712. doi:10.1093/ndt/gfaa231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。